Forbes

The Trump administration has initiated plans to reduce the Department of Education's workforce by half, with 2,000 employees placed on administrative leave.

The U.S. is set to impose a 25% tariff on all steel and aluminum imports, with Canadian metals facing an even higher 50% tax.

Elon Musk’s net worth dropped by $8.8 billion to $342.8 billion following a Tesla stock decline triggered by concerns over Trump’s tariffs.

Ukraine has agreed to a mineral development deal with the U.S., marking a shift in negotiations that previously included a demand for a $500 billion U.S.-controlled fund.

The United States is negotiating a deal with Ukraine for $500 billion worth of its natural resources, including titanium, lithium, and graphite, in exchange for military aid provided during Russia’s invasion.

A Bank of America survey shows fund managers are more optimistic than they’ve been in years, with cash holdings at their lowest levels since 2010 and 82% believing a global recession is unlikely in the next year.

Major corporations, including JPMorgan Chase, Morgan Stanley, Citigroup, and Coca-Cola, are rolling back or adjusting their DEI (Diversity, Equity, and Inclusion) commitments in response to political and legal pressures, particularly from the Trump administration’s policies.

Gold prices have surged to a record high of $2,938 per troy ounce, driven by President Donald Trump’s 25% blanket tariffs on aluminum and imports, accelerating its long-term rally.

Former President Donald Trump announced a 25% tariff on all steel and aluminum imports, effective February 10, 2025, as part of a broader trade protection strategy

The Trump administration has offered federal civilian employees a buyout option to resign with pay through September, creating confusion over its legality and congressional authority.

President Donald Trump’s new tariffs on Canada, Mexico, and China are expected to significantly increase prices for consumer goods, including cars, groceries, lumber, and products from overseas retailers like Temu and Shein.

The FDA has approved Vertex Pharmaceuticals’ Journavx, a non-opioid painkiller designed for adults with moderate to severe pain, marking the emergence of a new class of non-addictive medicines.